RNS Number : 5646S
Induction Healthcare Group PLC
07 November 2023
 

Induction Healthcare Group PLC

("Induction", the "Company", or the "Group")

 

Unaudited Interim Results

for the six months ended 30 September 2023

 

Induction (AIM: INHC), a leading digital health platform driving transformation of healthcare systems, announces its unaudited interim results for the six months ended 30 September 2023.

 

Financial Highlights

 

·    Revenues of £6.1m (H1 2022: £7.1m). New NHS patient portal contracts (revenue to be recognized in second half of this financial year) compensates for decline in NHS video conferencing usage.

·    Gross margin improvement to 75% (H1 2022: 66.1%). Improved management of direct cost base including cloud infrastructure.

·    Adjusted EBITDA of £0.01m (H1 2022: Loss £1.0m) Breakeven after non-cash adjustments.

·    Operating loss reduced to £2.4m (H1 2022: (£4.5m)). Ongoing cost containment programme continues to yield results.

·    Cash position £3.1m (FY23 YE: £4.3m). We remain on track towards our objective of self-sustaining growth and cash flow breakeven in FY24.

 

Operational Highlights

 

·    Awarded five new patient portal development contracts totaling £1.9m with several large Trusts/ICS and ICBs for the Zesty patient portal. In addition to the £1.4m announced in October, a further £538,000 is announced today:

Whittington Health NHS Trust worth £267,000 covering several patient portal projects including the use of Induction's Form Builder module for wait list validation, enhancing appointment management functionality, and integrating with Whittington's pre-surgical assessment tool.

Milton Keynes University Hospital worth £271,000 covering several patient portal projects related to reducing wait lists and launching an Induction video consultation from the patient portal.

·    Induction to be the first NHS-accredited portal to digitize maternity records for expectant mothers ensuring patient records are accessible within Zesty.

·    Completed roll out of NHS App integration with 6 new customers.  2.5 million patients can now access Zesty via the NHS App, up from 1 million patients at the beginning of April 2023.

·    One of only two patient portal providers to launch new functionality into the NHS App related to notifications, messages, and forms. This functionality is vital to supporting waitlist validation.

·    In final stages of engineering work which will enable patients to launch video consultation from within the patient portal, as well as enable clinicians to access a video consultation from their Electronic Medical Record (EMR) - integration of Zesty and Attend Anywhere platforms.

·    Non-core asset (Switch) sold for material consideration.

 

Paul Tambeau, CEO of Induction Healthcare, said: "With reports that over 8m patients will be on a waiting list by next year, Induction has a vital role to play in helping NHS Trusts manage their backlog and giving patients more choice in how they access care. We're well positioned to do this because of the work we've done on integrating our platforms and enhancing the features available through the NHS App. Improvement in both gross margin and operating losses also demonstrates the outcome of our cost containment work completed in the last 9 months which remains on track to achieve our goal of being breakeven this year."

 

 Enquiries

 

Induction

Christopher Samler, Chair

Paul Tambeau, Chief Executive Officer

 

+44 (0)7712 194092

+44 (0)7983 104443


 

 

 

Singer Capital Markets (Nominated Adviser and Broker)

+44 (0)20 7496 3000

 

Philip Davies

Alaina Wong

Jalini Kalaravy

 

 

 

About Induction - www.inductionhealthcare.com

Induction (AIM: INHC) Induction delivers a suite of software solutions that transforms care delivery and the patient journey through hospital. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.

 

Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.

 

CEO Review

Overview

 

Over the last six months, we have been focused on implementing our FY24 plan that was based on four goals:

 

1.    To be a profitable and sustainable growing business to deliver our commitments to shareholders.

2.    To successfully develop our Integrated Product.

3.    To be customer centric and commercial in everything we do.

4.    To implement and continuously develop an inclusive, performance driven and rewarding employee experience.

 

I am pleased to say that we are making strong progress on all four of these goals.

 

Through greater cost management, we are on track towards our objective of self-sustaining growth and cash flow breakeven in 2024. In addition to completing the cost containment measures started in Q4 FY23, an important driver has been better management of our cloud infrastructure. Our cloud costs are down c.50% compared to this time last year. In July 2023 we completed a major overhaul of our database infrastructure and are currently completing a significant change to our call screen which will generate further savings as well as improve user experience. There are additional projects we're evaluating to drive further savings in our cloud infrastructure.

 

In terms of sales growth, we have capitalised on the funding provided by the NHS to support Trusts to adopt or enhance their patient portal. We've been successful in securing £1.9m in new contracts which will fund key items on our integrated product roadmap, such as:

 

·    Digitizing maternity records for expectant mothers, as well as making diagnostic appointment details available from within the patient portal.

·    Enabling a patient to launch a video consultation from within the patient portal - integrating Attend Anywhere and Zesty.

·    Enhancing our appointment management functionality so that it can be used to support Patient Initiated Follow Up / and Clinician Initiated Follow Up initiatives.

·    Using our Form Builder module to support waitlist validation.

·    Deeping our integration with EMR partners such as Oracle Cerner, as well as other third-party systems.

 

Whilst the large majority of these new contracts are one time revenue, the enhanced platform will result in new features and case studies to support future sales.

 

We have made tangible progress in integrating our product, notably being able to launch a video consultation from within the patient portal. We expect this work to be completed in early Q4 FY24 and already have 3 customers contracted to adopt this functionality. We're also near completion of work to enable a clinician or staff member to launch a video consultation within their EMR.

 

We also continue to work closely with the NHS Wayfinder team in integrating new features into the NHS App. We are one of only two patient portal providers to launch new functionality into the NHS App related to notifications, messages, and forms. This functionality is vital to supporting waitlist validation. We've also completed roll out of NHS App integration with 6 new customers; 2.5 million patients can now access Zesty via the NHS App, up from 1 million patients at the beginning of April.

 

Consistent with our previously announced focus on our key strategic assets, we sold the Switch platform for a material consideration. We continue to look for a strategic buyer for the Guidance platform.

 

Financial Overview

 

We ended the first half of this year with £6.1m in recognised revenue, down from £7.1m over the same period last year. This decrease primarily reflects some Attend Anywhere contracts churning in England as well as lower than expected utilisation in Wales. This is offset by a 20% increase in Zesty revenue over the previous corresponding period. As we look to the full year, we note that most of the new NHS contracts will be recognised in the second half of the fiscal year, meaning a higher overall contribution from Zesty to revenue.

 

Gross margin in H1 improved to 75% compared to 66.1% in the same period last year. This demonstrates the improved management of direct cost base including cloud infrastructure.

 

Our operating loss was reduced in H1 to -£2.4m, an improvement from -£4.5m compared with the same period last year. This reflects that the ongoing cost containment programme continues to yield results. On an adjusted EBITDA position, we ended H1 at £0.01m compared to a loss of £1m over the same period last year.

 

From a cash perspective, we ended H1 with £3.1m, down from £4.3m at the end of FY23. The timing difference of the impact of post year end termination costs and delay in receipt of invoiced revenue accounts for this drop at the half year.

 

Outlook

 

With reports that over 8m patients will be on a waiting list by next year, we have a vital role to play in helping NHS Trusts manage their backlog and give patients more choice in how they access care. We're well positioned to do this because of the work we've completed on integrating our platforms and enhancing the features available through the NHS App. The NHS continues to prioritize further developments within the NHS App, enabling Induction to become more embedded in the health ecosystem. We're already seeing early evidence of the effectiveness of Induction's digital tools in supporting waitlist validation which positions us well for future growth.

 

We continue to see headwinds with Attend Anywhere renewals due to downward pressure on pricing, Trusts returning to more in-person appointments, and a post-Covid decline in the perceived advantages of video appointments.

 

We're also seeing increasing demand for integrating the capabilities of both our Zesty and Attend Anywhere platforms, creating a better experience for clinicians and patients.

 

Given the rightsizing changes we have already implemented, and the growth opportunities in front of us, we are increasingly confident about Induction's future as a leading player in the interface between the patient and their secondary care clinical teams.

 

Paul Tambeau

CEO

7 November 2023

 

 

Condensed Consolidated Statement of Comprehensive Income (Unaudited)

For the six months ended 30 September 2023

 


 

30 September 2023

 

30 September 2022


 

Unaudited 

 

Unaudited 


Note

£'000

 

£'000

Revenue from contracts with customers

2

6,057


7,118

Cost of sales


(1,514)


(2,414)

Gross Profit

 

4,543

 

4,704

Sales and marketing expenses

 3

(578)


(821)

Development expenses

 3

(4,652)


(4,159)

Administrative expenses

 3

(1,731)


(4,237)

Operating loss

 

(2,418)

 

(4,513)

Finance Costs

 

(2)


(4)

Finance Income


2


-

Loss before tax

 

(2,418)

 

(4,517) 

Taxation


-


(311)

Loss for the period from continuing operations

 

(2,418)

 

(4,828)

Profit / (Loss) from discontinued operations, net of tax

5

755


-

Loss for the period

 

(1,663)

 

(4,828)






Attributable to:





Equity holders of the parent


(1,663)


(4,828)



(1,663)

 

(4,828)






Loss per share from operations





- Basic

4

                       (0.03)


        (0.06)

- Diluted

 4

                       (0.03)


        (0.06)


Condensed Consolidated Statement of Comprehensive Income (Unaudited)

For the six months ended 30 September 2023

 



30 September 2023

 

30 September 2022



Unaudited 

 

Unaudited 


Note

£'000

 

£'000

Loss for the period


(1,663)

 

(4,828)

 





Other comprehensive income





Items that may be reclassified to profit or loss





Foreign currency translation differences


               (394)


               457

Reclassified to profit and loss during the period


                 162


               (801)

Other comprehensive income for the financial period


               (233)

 

             (344)

 





Total comprehensive loss for the financial period


(1,896)

 

(5,172)






Attributable to:





Equity holders of the parent


(1,896)


(5,172)



(1,896)

 

(5,172)











Loss per share:





Basic loss per share (£)

4

            (0.03)


            (0.06)

Diluted loss per share (£)

4

            (0.03)


            (0.06)

 

Condensed Consolidated Statement of Financial Position

As at 30 September 2023

 

 

30 September 2023

 

31 March      2023

 

 

Unaudited

 

Audited

 

Note

£'000

 

£'000

Non-current assets





Goodwill


10,685


10,685

Intangible Assets


13,005


15,251

Property, Plant and Equipment


7


9

Deferred tax assets


552


556

 Total non-current assets

 

24,249

 

26,501

Current assets





Trade and other receivables

6

2,165


2,672

Contract Assets


1,589


1,228

Current tax receivable


810


1,175

Cash and cash equivalents


3,055


4,287

Assets held for sale


2,474


2,474

 Total current assets

 

10,093

 

11,836

Total assets


34,342

 

38,337

Non-current liabilities





Contract liabilities


-


(3,588)

Deferred tax liabilities


(3,789)


(3,870)

Other financial liabilities


-


(56)

 Total non-current liabilities

 

        (3,789)

 

(1,235)

Current liabilities





Trade and other payables

7

(1,922)


(2,713)

Provisions


(25)


(528)

Contract liabilities


(4,846)


(2,198)

Liabilities associated with assets held for sale


(1,016)


(1,016)

Other financial liabilities


(91)


(72)

 Total current liabilities

 

(7,900)

 

(6,527)

Total liabilities


(11,689)

 

(14,041)

Net assets/(liabilities)


22,653

 

24,296






Equity attributable to equity holders of the parent





Share capital


462


462

Share premium


41,665


41,665

Merger reserve


20,205


20,205

Translation reserve


(405)


(162)

Other reserves


1,776


1,578

Accumulated deficit


(41,050)


(39,452)

 Total equity


22,653

 

24,296


Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 September 2023

 



Share

Share

Translation

Other

Merger

Accumulated

Total



Capital

Premium

reserve

reserve

reserve

deficit

equity



£'000

£'000

£'000

£'000

£'000

£'000

£'000

Balance at 1 April 2023


462

41,665

(162)

1,578

20,205

(39,452)

24,296

 









Total comprehensive loss for the period









Loss for the period


-

-

-

-

-

(1,663)

(1,663)

Other comprehensive loss for the period


-

-

(243)

-

-

-

(243)

Total comprehensive loss for the period


-

-

               (243)

-

-

(1,663)

(1,906)

Transactions with owners, in their capacity as owners









Equity-settled share-based payments


-

-

-

199

-

-

199










Total contributions by and distributions to owners


                -  

         -  

               -  

               199

              -  

                  -

     199

Balance at 30 September 2023

 

             462

        41,665

               (405)

               1,776

20,205

           (41,050)

     22,653

 

 

 

 

 

 

 

 

 

 

 


Condensed Consolidated Statement of Cash Flows

For the six months ended 30 September 2021

 

 

For the period ended

 

For the period ended

 

Note

30 September 2023

 

30 September 2022

 

 

£'000

 

£'000

Cash flows from operating activities





Loss for the financial period


(1,663)


(4,828)

Adjustments for:





Depreciation of property, plant and equipment


1


39

Amortisation and impairment of intangible assets


2,150


2,363

Finance costs


2


4

Finance income


(2)


-

Share-based payment expense


199


246

Taxation




311

Gain on sale of discontinued operations, net of tax


(750)


-



1,600


(2,963)

Decrease / (Increase) in trade and other receivables and contract assets


146


(1,500)

(Decrease) / Increase in trade and other payables and contract liabilities


(1,731)


7,303

(Decrease) / Increase in provisions


(503)


-

Interest received


2


-

Interest paid


(2)


(4)

Income taxes paid


-


(288)

Income taxes received


365


44

Net cash generated from / (used in) operating activities


(1,786)


(3,690)

Cash flows from investing activities





Payment of software development costs


-


(1,615)

Acquisitions of property, plant and equipment


-


(5)

Disposal of discontinued operations, net of cash


750


-

Net cash from investing activities

 

750


(1,620)

Cash flow from financial activities

 

 

 

 

Share issue proceeds


-


(194)

Payment of lease liabilities


(33)


-

Net cash from financing activities

 

(33)


(194)

Net increase in cash equivalents

 

(1,069)


1,876

Cash and cash equivalents at the beginning of the financial period


4,287


7,495

Effects of exchange rate changes on cash and cash equivalents


(163)


(393)

Cash and cash equivalents at the end of the financial period


3,055


8,978

Notes to the Condensed Consolidated Interim Financial Statements

 

1.   Accounting Policies

1.1.                Reporting entity

Induction Healthcare Group PLC ("Induction", the "Group" or the "Company") is publicly listed on the AIM market of the London Stock Exchange ("LSE"), and incorporated, domiciled and registered in the United Kingdom. The registered number is 11852026 and the registered address is 30 Crown Place, London, EC2A 4ES.

 

1.2.                Basis of preparation

These interim financial statements have been prepared and approved by the directors in accordance with International Financial Reporting Standards ("Adopted IFRSs"). They do not include all the information required for a complete set of IFRS financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the most recent annual consolidated financial information included in the annual report and accounts as of and for the year ended 31 March 2023.

 

The accounting policies applied are consistent with those applied in the most recent consolidated annual report and accounts for the year ended 31 March 2023, which are available on the Company's website at www.inductionhealthcare.com under "Investors - Financial reports & publications"

 

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Group obtained control and continue to be consolidated until the date when such control ceases. The financial information of the subsidiaries is prepared for the same reporting period as the Group, using consistent accounting policies. All intra-group balances, transactions, unrealised gains and losses resulting from intra-group transactions are eliminated in full.

 

Changes in the Group's interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

 

When the Group loses control over a subsidiary, the assets and liabilities are derecognised along with any related non-controlling interest and other components of equity.  Any resulting gain or loss is recognised in profit or loss.  Any interest retained in the former subsidiary is measured at fair value when control is lost.

 

These interim condensed consolidated financial statements are unaudited and were approved by the Board of Directors and authorised for issue on 6 November 2023 and are available on the Company's website at www.inductionhealthcare.com under "Investors - Financial reports & publications".


2.   Revenue

 2.1 Revenue by performance obligations

 

 

Period to 30 September 2023

 

Period to 30 September 2022

 

 

£'000

 

£'000

Provision of software

 

5,221


6,294

Post-contract support and maintenance


165


103

Set-up services


                  169 


                      30  

Professional services


225


492

Text message revenue


                 277 


                   199 

Total revenue from contracts with customers

 

6,057

 

7,118

 

3.   Expenses by nature



Period to 31 September 2023

 

Period to 30 September 2022



£'000

 

£'000

Employee benefit expense


3,686


4,809

Contractors


814


1,858

Amortisation of intangible assets


2,150


2,363

Depreciation of property, plant and equipment


1


39

Professional and legal fees


48


251

Research and development expense capitalised


-


(1,615)

 

4.   Earnings per share

Basic EPS is calculated by dividing the profit for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.

 

Diluted EPS is calculated by dividing the profit attributable to ordinary equity holders of the parent (after adjusting for interest on the convertible preference shares) by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

 

The following table reflects the income and share data used in the basic and diluted EPS calculations:

 

 

Loss attributable to ordinary shares (basic and diluted)

 

 

 

30 September

2023 

 

30 September

 2022


 

£'000

 

£'000

Loss attributable to ordinary shares used in calculating basic loss per share and diluted loss per share





From continuing operations


(2,418)


(4,828)

From discontinued operations


755


-


 

(1,663)

 

(4,828)

 

Weighted average number of ordinary shares (basic and diluted)

 


 

Period to 30 September 2023

 

Period to 30 September 2022

 

92,380,300

 

92,050,727

Issue of ordinary shares on exercise of equity settled share-based payments


-


329,573

Issued ordinary shares as at the end of the period

 

92,380,300

 

92,380,300

Weighted-average number of ordinary shares (basic and diluted)

 

92,380,300

 

92,206,033

 

 

Basic loss per share from continuing operations

(0.03)

(0.06)

Total basic loss per share

(0.03)

(0.06)

 

Diluted loss per share from continuing operations

(0.03)

(0.06)

Total diluted loss per share

(0.03)

(0.06)

5.   Discontinued operations

During June 2023, the Group completed the sale of the Induction Switch disposal Group for an undisclosed sum. This disposal Group was classified as held for sale in accordance with IFRS 5 "Non-current assets held for sale and discontinued operations" at 31 March 2023. The sale was completed in line with the Group's strategy to focus on sustainable growth.


6.   Trade and other receivables

 

 

30 September 2023

 

31 March 2023

 

 

£'000

 

£'000

Receivables from third-party customers


1,568


2,069

Other receivables


320


351

Prepayments


230


125

Social security and other taxes receivable


47


127

Total trade and other receivables

 

2,165

 

2,672

 

Trade receivables are non-interest bearing and are generally on terms of 30 days. Included within trade and other receivables is £nil expected to be recovered in more than 12 months.

7.   Trade and other payables

 

 

30 September 2023

 

31 March 2023

 

 

£'000

 

£'000

Trade payables


509


849

Accruals


             886


1,096

Social security and other taxes


              469


            703

Other payables


               58  


65  


 

1,922

 

2,713

Included within trade and other payables is £nil expected to be settled in more than 12 months

All trade and other payables are non-interest bearing and are normally settled on 30-day terms.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR DDBDBCUGDGXL